{
  "id": 12262253,
  "title": "Outset Medical director Braden Leonard buys $870,260 in shares",
  "url": "https://urgent.news/2026/10/05/outset-medical-director-braden-leonard-buys-870-260-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T23:50:21.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/outset-medical-director-braden-leonard-buys-870260-in-shares-93CH-4933110"
  },
  "original_language": "en",
  "account": "Outset Medical's Director and 10% Owner, Braden Leonard, made significant share purchases on October 1 and 2, 2026, for a total of $870,260. Prices per share ranged from $3.53 to $3.8758. The company's stock has seen a 38.5% return over the past week, although it remains down 72% over the previous year. InvestingPro analysis suggests the stock is undervalued at current prices. Mr. Leonard, through his company BML Investment Partners, L.P., acquired 228,334 shares on October 1 and an additional 16,575 shares on October 2. These shares are owned indirectly, with BML Capital Management, LLC serving as the general partner of BML Investment Partners, L.P., holding control. Mr. Leonard disclaims beneficial ownership of these shares, except for his financial interest. As managing member of BML Capital Management, LLC, he exercises investment and voting control. Following these acquisitions, his indirect beneficial ownership in Outset Medical stands at 2,764,610 shares. Investors can find more financial insights in the comprehensive Pro Research Report on InvestingPro. Outset Medical reported mixed results for the second quarter of 2026, with revenue of $31.6 million, beating the estimated $31.4 million. The adjusted loss per share was $0.80, higher than the expected $0.75 loss. Revenue increased by 1% from the prior year and 14% from the first quarter, indicating growing momentum. These developments suggest the company's efforts to improve financial performance. However, specific analyst reactions to these results have not been mentioned. Investors should note that stock performance in the market has not been detailed in the updates. The article was AI-generated and reviewed by an editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}